secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-110336
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical Q3 net loss $10.1M vs $4.6M; completes 209-patient VT trial, closes $50M placement
--------------------------------------------------------------------------------

- Net loss of $10.1M in Q3 2025, vs $4.6M in Q3 2024; cash $4.7M as of Sep 30, 2025.
- Completed enrollment of 209-patient FULCRUM-VT pivotal trial for vCLAS System VT ablation; demonstrated 97% acute effectiveness.
- Closed private placement on Oct 20, 2025 with gross proceeds up to $50M; upfront ~$19M to fund PMA submission.
- Appointed Deborah Kaster as Chief Financial Officer, adding to her role as Chief Business Officer.
- R&D expenses $2.8M; SG&A expenses $2.9M, down from $7.8M in prior year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000110465925110336/0001104659-25-110336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000110465925110336/adgm-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer